IDEXX Laboratories (NASDAQ:IDXX) Shares Acquired Rep. April McClain Delaney

Representative April McClain Delaney (D-Maryland) recently bought shares of IDEXX Laboratories, Inc. NASDAQ: IDXX. In a filing disclosed on May 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in IDEXX Laboratories stock on April 7th.

Representative April McClain Delaney also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of Bio-Techne NASDAQ: TECH on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 4/28/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 4/24/2025.
• Sold $1,001 - $15,000 in shares of A. O. Smith NYSE: AOS on 4/16/2025.
• Sold $1,001 - $15,000 in shares of A. O. Smith NYSE: AOS on 4/10/2025.
• Sold $1,001 - $15,000 in shares of Toro NYSE: TTC on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Bio-Techne NASDAQ: TECH on 4/9/2025.
• Purchased $1,001 - $15,000 in shares of IDEXX Laboratories NASDAQ: IDXX on 4/9/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 4/9/2025.

IDEXX Laboratories Trading Up 0.7 %

Shares of IDXX stock opened at $475.07 on Tuesday. The firm has a market capitalization of $38.50 billion, a P/E ratio of 44.52, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $548.88. The firm's fifty day simple moving average is $419.61 and its 200 day simple moving average is $428.18. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The business's revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.71 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on IDXX shares. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $524.75.

Hedge Funds Weigh In On IDEXX Laboratories

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in shares of IDEXX Laboratories by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company's stock valued at $948,279,000 after acquiring an additional 37,734 shares during the last quarter. Bamco Inc. NY raised its position in IDEXX Laboratories by 4.3% in the 4th quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after purchasing an additional 82,264 shares during the last quarter. Franklin Resources Inc. boosted its stake in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after purchasing an additional 34,305 shares in the last quarter. Invesco Ltd. grew its holdings in shares of IDEXX Laboratories by 6.8% during the fourth quarter. Invesco Ltd. now owns 1,160,988 shares of the company's stock worth $479,999,000 after purchasing an additional 74,324 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after buying an additional 414,802 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares of the company's stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by company insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.